Related Experiment Video
Updated: Aug 24, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Anticoagulation in atrial fibrillation
1Rhode Island Hospital/Brown Medical School, USA.
Insights
Warfarin anticoagulation is the most effective stroke prevention for atrial fibrillation (AF). Stroke risk factors like age and hypertension necessitate careful consideration for warfarin therapy, even in paroxysmal AF.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Atrial fibrillation (AF) significantly increases stroke risk.
- Warfarin is the gold standard for anticoagulation in AF.
- Aspirin offers limited stroke protection compared to warfarin.
Purpose of the Study:
- To review the efficacy and risks of warfarin for stroke prevention in AF.
- To identify key stroke risk factors in AF patients.
- To discuss the role of anticoagulation in different AF types and with other therapies.
Main Methods:
- Literature review of studies on anticoagulation for AF.
- Analysis of stroke risk factors and their impact on treatment decisions.
- Comparison of warfarin with aspirin and other antithrombotic agents.
Main Results:
- Warfarin significantly reduces stroke risk in AF patients with a target INR of 2-3.
- Key stroke risk factors include age >65, hypertension, prior stroke, and heart failure.
- Combined warfarin and aspirin increases bleeding risk.
- Paroxysmal AF carries similar stroke risk to persistent AF, requiring anticoagulation.
- Antiarrhythmic therapy does not negate the need for anticoagulation.
Conclusions:
- Warfarin remains the most effective anticoagulation for AF stroke prevention.
- Risk stratification is crucial for guiding warfarin therapy.
- Newer antithrombotic agents may offer future alternatives.
Abstract:
Anticoagulation with warfarin is the most effective means of reducing stroke in AF. The generally recommended INR goal is 2-3. Aspirin provides a modest degree of stroke protection in AF but is inferior to warfarin. Assessment of stroke risk is critical in determining whether to prescribe warfarin therapy to a patient with AF. The most important risk factors for stroke in AF are age over 65 years, hypertension, prior stroke, and left ventricular dysfunction or heart failure. The risk of warfarin may be less than commonly believed, but increases when warfarin is combined with aspirin. Patients with paroxysmal AF are not at lower risk of stroke than those with persistent AF and should be treated with warfarin. Apparently successful therapy with antiarrhythmic agents does not eliminate the need for anticoagulation. New antithrombotic therapies are being studied and may soon provide an alternative to warfarin.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Clot Retraction and Fibrinolysis
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Aortic Regurgitation III: Medical Management

